STOCKS TELEGRAPH

Tag: Seres Therapeutics

  • 3 Stocks That Could Climb Higher Soon: Electromed (ELMD), Seres Therapeutics (MCRB), Cardiol Therapeutics (CRDL)

    3 Stocks That Could Climb Higher Soon: Electromed (ELMD), Seres Therapeutics (MCRB), Cardiol Therapeutics (CRDL)

    As the biotech landscape evolves, the balance between innovation and accountability has never been more important. With investors prioritizing efficiency and clear returns, organizations must demonstrate a sharper focus on delivering results. This shift places greater emphasis on smart resource management, strategic clinical development, and early regulatory engagement as key drivers of consistent and scalable growth.

    Electromed Inc (ELMD)

    Electromed Inc (NYSEAMERICAN: ELMD) opened the trading on May 04, 2026, with a bit cautious approach as it glided -0.16% to $25.56. During the day, the stock rose to $26.54 and sunk to $25.44. Taking a more long-term approach, ELMD posted a 52-week range of $17.73-$30.73.

    The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 12.39%. Meanwhile, its Annual Earning per share during the time was 12.39%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 29.41%. This publicly-traded company’s shares outstanding now amounts to $8.28 million, simultaneously with a float of $6.85 million. The organization now has a market capitalization sitting at $211.52 million.

    Seres Therapeutics Inc (MCRB)

    Seres Therapeutics Inc (NASDAQ: MCRB) started the day on May 04, 2026, with a price increase of 1.05% at $7.69. During the day, the stock rose to $8.29 and sunk to $7.63. Taking a more long-term approach, MCRB posted a 52-week range of $6.53-$29.98.

    Nevertheless, stock’s Earnings Per Share (EPS) this year is -1385.94%. This publicly-traded company’s shares outstanding now amounts to $9.56 million, simultaneously with a float of $7.28 million. The organization now has a market capitalization sitting at $74.07 million. It’s Quick Ratio in the last reported quarter now stands at 2.56.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is positioning itself for long-term growth by expanding beyond its lead program into broader cardiovascular indications. This strategic pipeline diversification reflects a focus on capturing value in large, underserved markets where inflammation and fibrosis remain key drivers of disease progression.

    Market Momentum

    As of May 4, 2026, CRDL closed at $1.33, down 2.92%, with trading volume (546,678 shares) below its average of 678,166 shares—indicating moderate selling pressure. With a market cap of $148.535M and a beta of 0.43, the stock continues to demonstrate relatively low volatility. It remains within its 52-week range ($0.8800–$1.71), while a 1-year target estimate of $7.49 suggests meaningful upside potential as pipeline programs advance.

    Pipeline Expansion: CRD-38

    Cardiol is developing CRD-38, a next-generation, subcutaneous therapy designed for improved dosing convenience and broader clinical use. The therapy targets both inflammation and fibrosis, addressing two critical mechanisms underlying heart failure progression that are not fully treated by current therapies.

    Market Opportunity

    Heart failure represents a multi-billion-dollar global market with millions of patients and limited treatment options specifically targeting inflammatory pathways. By advancing CRD-38, Cardiol is positioning itself to enter a large and underserved segment, significantly expanding its long-term commercial opportunity beyond pericarditis and myocarditis.

    Outlook

    As CRD-38 progresses toward clinical development, it could emerge as a key value driver. Successful advancement would strengthen Cardiol’s growth profile and support its transition into a more diversified cardiovascular biotech company.

  • Seres Therapeutics Inc. (MCRB) stock plunged in the premarket trading session; here’s why

    It was observed in the last check, that Seres Therapeutics Inc. (MCRB stock) shares had plunged in the premarket trading session. The double-digit plunge had shed-58.09% off of the share price bringing it at $8.73 in pre-market. MCRB stock had closed the previous session on Thursday with a gain of 0.48% at $20.83. The MCRB stock volume traded 0.87 million shares, while in the past 50 days the average trade volume per day was around 0.87 million shares. In the past year up to date, MCRB shares have jumped by 338.53% and in the past week, the MCRB stock moved up by 1.61%. In the past three and six months, the stock has gained 1.66% and shed -17.99% respectively. Furthermore, the company is currently valued at $1.86 billion and has 91.53 million outstanding shares.

    About Seres Therapeutics Inc.

    Seres Therapeutics Inc. is a biotechnology company that specifically focuses on the development, discovery, and licensing of disease-treating therapeutics. The therapeutics is based on a microbiome platform that creates bacterial consortia. The bacterial consortia’s primary function is to interact with the host cells and tissues in a therapeutic way to treat the disease.

    The organization’s lead item up-and-comer is the SER-109, an oral microbiome helpful competitor that has finished Phase III clinical preliminary for the treatment of clostridium difficile disease (CDI). It is likewise creating SER-287 that is in Phase IIb clinical preliminary to treat ulcerative colitis; SER-401, which is in Phase Ib clinical preliminary for use with designated spot inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical preliminary for the treatment of incendiary entrail sickness. What’s more, the organization participates in the improvement of SER-262 to treat an underlying repeat of CDI; and SER-155, a developed microorganisms microbiome drug intended to forestall mortality because of gastrointestinal contaminations, bacteremia, and join versus have illnesses in immunocompromised patients getting allogeneic hematopoietic undifferentiated cell transplantation and organ transfers.

    The company’s platform and progress allows it to have licensing partnerships with other medical institutions and firms across the industry. It has made these sort of partnerships with Memorial Sloan Kettering Cancer Center and NestecLTd. The company was originally formed in 2010 by the name of Seres Health Inc. which was changed in May 2015. Furthermore, the headquarter of the company lies in Cambridge, Massachusetts.

    MCRB stock is holding a meeting regarding the topline results of the phase 2b trial of ECO-RESET study

    By Easter Time 8:30 am today, the MCRB stock had been hosting a conference call and live audio webcast. This conference was specifically hosted by the management team at Seres Therapeutics Inc. The main reason for hosting this live call and conference is to address the results from the phase 2b ECO-RESET study which had evaluated SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The company provided topline results for this phase 2b study which listed that the Essential endpoint of clinical abatement contrasted with fake treatment was not accomplished; both dosing regimens of SER-287 were for the most part very much endured; open name and support parts of the SER-287 examination will be shut and Microbiome endpoints and examinations expected in the second 50% of 2021.